Table 3.
Wound Characteristics and Outcomes
| Characteristic | No Anticoagulation or Antiplatelet Therapy (n = 67) |
Anticoagulation or Antiplatelet Therapy (n = 122) |
P |
|---|---|---|---|
| Mean initial wound size (cm2) | 58.5 ± 63.1 | 47.0 ± 59.3 | 0.220 |
| Mean no. previous debridements | 3.6 ± 2.1 | 3.9 ± 2.3 | 0.401 |
| Mean days of follow-up | 369.5 ± 352.5 | 458.4 ± 343 | 0.095 |
| Use of dermal matrix | 52 (77.6%) | 91 (74.6%) | 0.643 |
| 30 d outcomes | |||
| Mean size at 30 d (cm2) | 11.5 ± 19.0 | 9.1 ± 17.3 | 0.412 |
| Mean % take at 30 d | 75.3 ± 28.3 | 70.6 ± 41.4 | 0.376 |
| Success at 30 d | 18 (26.9%) | 30 (24.6%) | 0.731 |
| No follow-up at 30 d | 3 (4.5%) | 11 (9.0%) | 0.254 |
| Final outcomes | |||
| Weeks to complete healing | 19.9 ± 21.8 | 22.7 ± 28.3 | 0.600 |
| Complete healing at final follow-up | 46 (68.7%) | 92 (75.4%) | 0.317 |
| Lost to follow-up | 10 (14.9%) | 8 (6.6%) | 0.061 |
Wound characteristics and outcomes of STSG patients with lower extremity wounds were documented throughout follow-up. Data are reported as mean ± SD or n (percent).